Ruminations of a Taco-Obsessed Philly Native

UPDATE — Octoer 17th, 2016 — Seattle Genetics makes good on their word to hire 100 more employees : http://www.bizjournals.com/seattle/blog/health-care-inc/2016/03/seattle-genetics-ambitious-plan-for-12-more-drugs.html


 

Seattle Genetics is a biotechnology company that are leaders in the study of antibody drugs to treat cancer. The company was started in 1998 in Bothell, Washington by Clay Siegall. Bothell, Washington is a suburb of Seattle. The company employs some five hundred to one thousand employees.

The technology at Seattle Genetics takes monoclonal antibodies to kill cancerous cells. Their leading study is the ADCETRIS. The ADCETRIS is the first of the ADCs tests. ADC stands for antibody drug conjugates.

Clay Siegall is the present president and the founder of Seattle Genetics. He studied at the University of Maryland to earn a Bachelor of Science, Zoology degree. He was alumnus of the year in computer, math and science at University of Maryland. Clay Siegall went on to The George Washington University to earn a Ph. D in Genetics. Pacific Northwest Ernst and Young voted him entrepreneur of the year in 2012.

Clay Siegall is additionally the director of many biotechnology companies. He is the director of Alder Biopharmaceuticals, Mirna Therapeutics and Ultragenyx Pharmaceutical.

Dr. Clay Siegall started Seattle Genetics because he has always focused on treating cancer. The purpose of Seattle Genetics is to develops ADCs to treat all types of cancers. With Dr. Clay Siegall leading the company, Seattle Genetics has made over three hundred million dollars. The company has additionally secured more licenses for their ADCs technology under Dr. Siegall’s leadership. Seattle Genetics now have licenses with Genentech, AbbVie, GlaxoSmithKline and Plitzer, which help to improve the ADCs cancer fighting technology.

NO COMMENTS

You must be logged in to post a comment.